Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy

Keyphrases

• Dose-dense 100%
• Neoadjuvant 100%
• Methotrexate 100%
• Radical Cystectomy 100%
• Cisplatin 100%
• Vinblastine 100%
• Gemcitabine 100%
• Bladder Cancer 100%
• Doxorubicin 100%
• Locally Advanced Bladder Cancer 15%
• Neoadjuvant Chemotherapy 15%
• Survival Rate 10%
• High Risk 10%
• Clinical Trials 5%
• Received Dose 5%
• Muscle-invasive Bladder Cancer 5%
• Urothelial Cancer 5%
• Risk of Death 5%
• Improved Survival 5%
• Complete Pathological Response 5%
• Cox Regression Analysis 5%
• Overall Mortality 5%
• Inclusion Criteria 5%
• Kaplan-Meier Estimator 5%
• Cox Proportional Hazards Regression Model 5%
• Multivariable Cox Regression 5%
• Lymph Node Invasion 5%
• Overall Survival 5%
• Pathological Response 5%
• Evidence Support 5%
• Low Dose Rate 5%
• Cisplatin-based Chemotherapy 5%
• Neoadjuvant Cisplatin 5%
• Cystectomy 5%
• Level I Evidence 5%
• Retrospective Cohort 5%
• Hydronephrosis 5%
• Multivariable 5%

Medicine and Dentistry

• Gemcitabine 100%
• Doxorubicin 100%
• Cisplatin 100%
• Methotrexate 100%
• Bladder Cancer 100%
• Vinblastine 100%
• Lenabasum 100%
• Dose Densification 100%
• Cystectomy 100%
• Neoadjuvant Chemotherapy 15%
• Arm 10%
• Proportional Hazards Model 10%
• Survival Rate 10%
• Clinical Trial 5%
• Chemotherapy 5%
• Lymph Node 5%
• Disease 5%
• Muscle Invasive Bladder Cancer 5%
• Kaplan Meier Method 5%
• Hydronephrosis 5%
• Patient-Data 5%
• Urothelial Cancer 5%
• Overall Survival 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Methotrexate 100%
• Doxorubicin 100%
• Vinblastine 100%
• Lenabasum 100%
• Gemcitabine 100%
• Bladder Cancer 100%
• Cisplatin 100%
• Chemotherapy 20%
• Survival Rate 10%
• Overall Survival 5%
• Clinical Trial 5%
• Hydronephrosis 5%
• Disease 5%
• Malignant Neoplasm 5%
• Muscle Invasive Bladder Cancer 5%